By analyzing gene expression profiles of rituximab (CD20-specific antibody) responsive and unresponsive cell lines of DLBCL, researchers found that rituximab affected not only the expression of genes related to classical pathway but also TGF-β and Wnt signalings.[31] A previous study indicated that FOXP1 could enhance Wnt/β-catenin signaling and improve the sensitivity to Wnt signaling inhibitors in DLBCL.[32] The combination therapy targeting KIF23 and these pathways may provide a new treatment for DLBCL. Here, KIF23 is linked to diffuse large B-cell lymphoma.